Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus
| Autor: | Michael Wagner, Elisabeth Defossa |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Molecular Structure
Chemistry Organic Chemistry Clinical Biochemistry Administration Oral Pharmaceutical Science Incretin Type 2 Diabetes Mellitus Enteroendocrine cell Type 2 diabetes Pharmacology medicine.disease Biochemistry Receptors G-Protein-Coupled Diabetes Mellitus Type 2 Free fatty acid receptor 1 Drug Discovery medicine Humans Hypoglycemic Agents Molecular Medicine Receptor Molecular Biology Glycemic G protein-coupled receptor |
| Zdroj: | Bioorganic & Medicinal Chemistry Letters. 24:2991-3000 |
| ISSN: | 0960-894X |
| Popis: | Despite the availability of established medication for treatment of type 2 diabetes mellitus (T2DM) there still remains a significant unmet need for new effective, oral antidiabetic agents that improve glycemic control while maintaining an excellent safety profile. In this regard the FFA1 receptor has emerged as an attractive target in recent years. Activation of the FFA1 receptor has been shown to not only amplify glucose induced insulin secretion from pancreatic beta cells but also to stimulate incretin secretion from intestinal endocrine cells. The current review highlights on the latest developments and clinical data from evolving research on the potential of FFA1 agonists as effective treatment for T2DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect